These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 9555552)

  • 21. p53 but not erbB-2 expression is associated with rapid tumor proliferation in urinary bladder cancer.
    Moch H; Sauter G; Mihatsch MJ; Gudat F; Epper R; Waldman FM
    Hum Pathol; 1994 Dec; 25(12):1346-51. PubMed ID: 8001930
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Overexpression of c-erbB-2 and p53 oncoprotein in renal pelvic and ureteral carcinomas with reference to the expression of Ki-67 antigen as a proliferation marker].
    Hashimoto H; Sue Y; Tokumitsu M; Saga Y; Yachiku S
    Nihon Hinyokika Gakkai Zasshi; 1997 Jun; 88(6):605-11. PubMed ID: 9234617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deoxyribonucleic acid content and survival rates of patients with transitional cell carcinoma of the bladder.
    al-Abadi H; Nagel R
    J Urol; 1994 Jan; 151(1):37-42. PubMed ID: 8254829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
    Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
    Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunohistochemical analysis of proliferating cell nuclear antigen, p53 protein and nm23 protein, and nuclear DNA content in transitional cell carcinoma of the bladder.
    Shiina H; Igawa M; Nagami H; Yagi H; Urakami S; Yoneda T; Shirakawa H; Ishibe T; Kawanishi M
    Cancer; 1996 Oct; 78(8):1762-74. PubMed ID: 8859190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
    Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
    Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy.
    Nakopoulou L; Constantinides C; Papandropoulos J; Theodoropoulos G; Tzonou A; Giannopoulos A; Zervas A; Dimopoulos C
    Urology; 1995 Sep; 46(3):334-40. PubMed ID: 7660508
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Apoptosis, p53, bcl-2, and Ki-67 in invasive bladder carcinoma: possible predictors for response to radiochemotherapy and successful bladder preservation.
    Rödel C; Grabenbauer GG; Rödel F; Birkenhake S; Kühn R; Martus P; Zörcher T; Fürsich D; Papadopoulos T; Dunst J; Schrott KM; Sauer R
    Int J Radiat Oncol Biol Phys; 2000 Mar; 46(5):1213-21. PubMed ID: 10725634
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates.
    Nakopoulou L; Vourlakou C; Zervas A; Tzonou A; Gakiopoulou H; Dimopoulos MA
    Hum Pathol; 1998 Feb; 29(2):146-54. PubMed ID: 9490274
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of p53 and Ki-67 immunomarkers in carcinoma of urinary bladder.
    Thakur B; Kishore S; Dutta K; Kaushik S; Bhardwaj A
    Indian J Pathol Microbiol; 2017; 60(4):505-509. PubMed ID: 29323062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunohistochemical expression of p63, p53 in urinary bladder carcinoma.
    Koyuncuer A
    Indian J Pathol Microbiol; 2013; 56(1):10-5. PubMed ID: 23924551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. P53 and ploidy assessed by flow cytometry in bladder washings.
    Griffiths TR; Mellon JK; Pyle GA; Shenton BK; Neal DE
    Br J Urol; 1995 Nov; 76(5):575-9. PubMed ID: 8535675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proliferative status is a risk index for recurrence in primary superficial (pTa/T1) low-grade urothelial bladder carcinoma.
    Su JS; Arima K; Hasegawa M; Franco OE; Yanagawa M; Sugimura Y; Kawamura J
    Hinyokika Kiyo; 2003 Nov; 49(11):649-58. PubMed ID: 14719452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Prognostic value of the immunohistochemical expression of: Ki67, p53, PCNA and Bcl2 in the superficial tumors of the bladder].
    Rammeh-Rommani S; Zermani R; Sfaxi M; Chabchoub A; Zouari B; Ayed M; Ben Jilani-Baltagi S
    Tunis Med; 2007 Jun; 85(6):509-12. PubMed ID: 17644907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of p53, Ki-67, microstaging and microvessel density in pT1G3 bladder tumors: creation of risk groups for progression.
    Queipo-Zaragoza JA; Ruiz-Cerda JL; Vera-Donoso CD; Vera-Sempere F; Budia-Alba A; Jimenez-Cruz JF
    Scand J Urol Nephrol; 2007; 41(4):283-9. PubMed ID: 17763218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of Ki-67 antigen and p53 protein in urinary bladder cancer: immunohistochemical analysis of radical cystectomy specimens.
    Tsuji M; Kojima K; Murakami Y; Kanayama H; Kagawa S
    Br J Urol; 1997 Mar; 79(3):367-72. PubMed ID: 9117215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Muscle invasive schistosomal squamous cell carcinoma of the urinary bladder: frequency and prognostic significance of p53, BCL-2, HER2/neu, and proliferation (MIB-1).
    Badr KM; Nolen JD; Derose PB; Cohen C
    Hum Pathol; 2004 Feb; 35(2):184-9. PubMed ID: 14991535
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DNA ploidy and p53 protein expression in superficial transitional cell carcinoma of the bladder.
    Ioakim-Liossi A; Pantazopoulos D; Karakitsos P; Athanassiadou P; Aroni K; Chourdakis N; Giachnaki A; Athanassiades P
    Cytopathology; 2000 Apr; 11(2):96-103. PubMed ID: 10772009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FOXO1 down-regulation is associated with worse outcome in bladder cancer and adds significant prognostic information to p53 overexpression.
    Lloreta J; Font-Tello A; Juanpere N; Frances A; Lorenzo M; Nonell L; de Muga S; Vázquez I; Cecchini L; Hernández-Llodrà S
    Hum Pathol; 2017 Apr; 62():222-231. PubMed ID: 28087474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. THE PROGNOSTIC SIGNIFICANCE OF P53, BCL2 AND MIB1 EXPRESSIONS RELATED WITH OTHER CLINICOPATHOLOGICAL VARIABLES IN SEROUS OVARIAN CARCINOMAS. A CLINICOPATHOLOGICAL STUDY IN PERITONEAL FLUIDS.
    Kalogeraki A; Tamiolakis D; Matalliotaki C; Karvela-Kalogeraki I; Karvelas-Kalogerakis M; Segredakis J; Sinatkas V; Matalliotakis I
    Rev Med Chir Soc Med Nat Iasi; 2015; 119(2):454-60. PubMed ID: 26204652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.